Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus from six analysts (4 buy, 1 hold, 1 sell) with an average 12‑month price target of $14.25.
• Orchestra BioMed beat quarterly estimates — $0.26 EPS vs. -$0.38 expected and $30.92M revenue vs. $0.93M expected — but still reported a negative net margin and analysts forecast about -$1.66 EPS for the fiscal year.
• Insider David P. Hochman purchased 10,000 shares at $4.29 and insiders own 8.10% of the company; shares trade near $4.13 with a market cap of roughly $241.7M and ~53% institutional ownership.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $14.25.

A number of brokerages have recently issued reports on OBIO. Barclays upped their target price on shares of Orchestra BioMed from $11.00 to $12.00 and gave the company an "overweight" rating in a research note on Friday, January 9th. Wall Street Zen upgraded shares of Orchestra BioMed from a "strong sell" rating to a "hold" rating in a research note on Saturday, March 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Orchestra BioMed in a research note on Thursday, April 2nd. Finally, Chardan Capital restated a "buy" rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $4.13 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.45 and a quick ratio of 6.43. The firm has a 50-day moving average of $4.25 and a two-hundred day moving average of $4.11. The stock has a market cap of $241.69 million, a P/E ratio of -3.65 and a beta of 0.60. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.64. The company had revenue of $30.92 million during the quarter, compared to analysts' expectations of $0.93 million. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. On average, research analysts expect that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year.

Insider Activity

In related news, insider David P. Hochman bought 10,000 shares of the business's stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the insider owned 1,086,467 shares in the company, valued at $4,660,943.43. This trade represents a 0.93% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 8.10% of the company's stock.

Institutional Investors Weigh In On Orchestra BioMed

A number of institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC raised its stake in shares of Orchestra BioMed by 9.2% in the 3rd quarter. Citadel Advisors LLC now owns 54,002 shares of the company's stock valued at $134,000 after purchasing an additional 4,561 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Orchestra BioMed by 35.7% in the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock valued at $58,000 after purchasing an additional 5,678 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $38,000. Virtu Financial LLC acquired a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $57,000. Finally, Creative Planning acquired a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 53.20% of the company's stock.

About Orchestra BioMed

Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.